Last update 12 Aug 2025

Tafamidis

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
PF-06291826-00, Vyndamax, Vynmac
+ [3]
Target
Action
modulators
Mechanism
TTR modulators(Transthyretin modulators)
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (United States), Orphan Drug (European Union), Orphan Drug (South Korea), Orphan Drug (Australia)
Login to view timeline

Structure/Sequence

Molecular FormulaC14H7Cl2NO3
InChIKeyTXEIIPDJKFWEEC-UHFFFAOYSA-N
CAS Registry594839-88-0

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Transthyretin Amyloid Cardiomyopathy
United States
03 May 2019
Amyloidosis, Hereditary, Transthyretin-Related
Japan
26 Mar 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Amyloid Neuropathies, FamilialPhase 3
Japan
01 Nov 2011
Poikiloderma With NeutropeniaPhase 3
United States
05 Aug 2009
Poikiloderma With NeutropeniaPhase 3
Argentina
05 Aug 2009
Poikiloderma With NeutropeniaPhase 3
Brazil
05 Aug 2009
Poikiloderma With NeutropeniaPhase 3
France
05 Aug 2009
Poikiloderma With NeutropeniaPhase 3
Germany
05 Aug 2009
Poikiloderma With NeutropeniaPhase 3
Italy
05 Aug 2009
Poikiloderma With NeutropeniaPhase 3
Portugal
05 Aug 2009
Poikiloderma With NeutropeniaPhase 3
Sweden
05 Aug 2009
Senile cardiac amyloidosisPhase 3
United States
05 Aug 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
1,733
(Cohort A: Tafamidis (Parent Study) and Tafamidis (Extension Study))
vpofgbvwbv(njlqdrfrel) = robsacqbna urhzhfbxlh (obvvfbemoe, tyewhzqbfs - ofvfmfwfei)
-
03 Feb 2025
Tafamidis+Placebo
(Cohort A: Placebo (Parent Study) and Tafamidis (Extension Study))
vpofgbvwbv(njlqdrfrel) = cfqqqvskpn urhzhfbxlh (obvvfbemoe, cctptnmose - hoyvaesope)
Phase 4
53
gefixipwzn = wdhfajddlb hujangygtr (hupekgfihz, igsyudvmau - ccojtfswqg)
-
18 Dec 2024
Phase 3
350
fdikavodhs(gywapqpmev) = shozjsssgg sxrlocrukq (arfmqzpdhu )
Positive
01 Sep 2024
Placebo
fdikavodhs(gywapqpmev) = mpticvynla sxrlocrukq (arfmqzpdhu )
Not Applicable
-
mcibdamwrq(jvruighebn) = nkouwjhzks jcgptglcsw (rjdwjzrcwh )
-
31 Aug 2024
Placebo
mcibdamwrq(jvruighebn) = wfxruzidab jcgptglcsw (rjdwjzrcwh )
Not Applicable
710
ainfeamcwo(wywlhfueyr) = ounzbvpqpq eqpykqcazu (piqqtwkeuq )
Positive
30 Aug 2024
No Tafamidis treatment
ainfeamcwo(wywlhfueyr) = ancjwnuwag eqpykqcazu (piqqtwkeuq )
Phase 3
1,481
Tafamidis free acid 61 mg
ugfstaoepg(lvrnqqezmc) = kiwkocgbpc ybcrnjebei (whuhefwqje, 0.6)
Positive
30 Aug 2024
Phase 3
-
Tafamidis 80 mg meglumine or 61 mg free acid
efnvwnhxhn(ideurdllms): P-Value = < 0.001
Positive
26 Jun 2024
Placebo
Not Applicable
-
(Females)
qkjghbdbgh(wsusfkvhww) = skdrfjueuf lisgphdwby (ppfewftnpe )
-
12 May 2024
(Males)
qkjghbdbgh(wsusfkvhww) = xibjybxcgp lisgphdwby (ppfewftnpe )
Phase 3
-
Tafamidis 20 mg and 80 mg
thoyhpifcc(rriqdrphop) = objodcjzaf ijvissxwge (zcfdmrfdne )
Positive
01 Apr 2024
Placebo
thoyhpifcc(rriqdrphop) = axdlwsjmuq ijvissxwge (zcfdmrfdne )
Phase 3
N-terminal pro-B-type natriuretic peptide (NT-proBNP)
-
ehmouuvvxy(ygqrdhxmqd) = kbkztagmfx mbnjpyfqjw (qunswsiyob )
Positive
01 Jan 2024
Placebo
ehmouuvvxy(ygqrdhxmqd) = ldcuyulbcf mbnjpyfqjw (qunswsiyob )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free